FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2553936756> ?p ?o ?g. }

• W2553936756 abstract "Abstract Acute lymphoblastic leukemia (ALL) represents a rare malignancy in the elderly and few authors have specifically focused on the treatment of ALL in this setting. We recently published the results of a prospective phase II study comprising an induction therapy with vincristine, Daunoxome, cyclophosphamide and prednisone (VDXD) given to 15 patients aged ≥ 60 years. Here, we updated the results after enrolling 17 patients treated from 1999 to 2002 (median age 69 years, range 61–79) and we compared these with the results obtained in 17 elderly patients treated according to the GIMEMA ALL 0288 protocol from 1994 to 1998 (median age 70, range 61–76). Most of patients in both groups had B-lineage ALL and an initial WBC count less than 30 x 109/L. The most frequent karyotypic abnormality resulted the Ph which was detected in 4 (23%) and in 3 patients (17%) treated with 0288 and VDXD, respectively. BCR-ABL translocation was present in 45 % of patients treated with VDXD. Comorbidities were documented in 11 (65 %) patients treated with VDXD compared with 9 (58%) receiving 0288 regimen. With VDXD combination elderly ALL had a higher CR rate than with 0288 protocol (76.5% vs 41%; p=0.037) likely due to both lower induction mortality (17.5% vs 35%; p=0.028) and less resistant disease (6% vs 24%; p=0.025). Infectious complications rate was similar (64% vs 53%) but they were the primary cause of death in 2 and 5 patients receiving VDXD and 0288, respectively. Non-hematological side effects were comparable. Median DFS was similar and resulted 18 months and 20 months with 0288 and VDXD treatment, respectively. Median EFS was 3.9 and 12.8 months, respectively (p = 0.0486). Particularly, 1-year EFS resulted 35% in patients receiving 0288 treatment compared with 53% in those given VDXD. Median OS was 4.5 an 21 months in the first and in the latter group of patients (p = 0.0239) with a two-year OS of 29% in 0288 and 38% in VDXD group. Our results are encouraging and show that the administration of high-dose daunorubicin as liposomal compound in elderly ALL patients is not only feasible but also able to improve CR rate, EFS and OS without increase in toxicity." @default.
• W2553936756 created "2016-11-30" @default.
• W2553936756 creator A5000684645 @default.
• W2553936756 creator A5017681466 @default.
• W2553936756 creator A5024306596 @default.
• W2553936756 creator A5026441738 @default.
• W2553936756 creator A5029722841 @default.
• W2553936756 creator A5046242522 @default.
• W2553936756 creator A5071273767 @default.
• W2553936756 creator A5083644983 @default.
• W2553936756 creator A5086831338 @default.
• W2553936756 creator A5087011523 @default.
• W2553936756 date "2004-11-16" @default.
• W2553936756 modified "2023-09-30" @default.
• W2553936756 title "Comparison of Two Regimens for the Treatment of Elderly Patients with Acute Lymphoblastic Leukaemia (ALL)." @default.
• W2553936756 doi "https://doi.org/10.1182/blood.v104.11.4490.4490" @default.
• W2553936756 hasPublicationYear "2004" @default.
• W2553936756 type Work @default.
• W2553936756 sameAs 2553936756 @default.
• W2553936756 citedByCount "5" @default.
• W2553936756 countsByYear W25539367562012 @default.
• W2553936756 countsByYear W25539367562016 @default.
• W2553936756 countsByYear W25539367562017 @default.
• W2553936756 crossrefType "journal-article" @default.
• W2553936756 hasAuthorship W2553936756A5000684645 @default.
• W2553936756 hasAuthorship W2553936756A5017681466 @default.
• W2553936756 hasAuthorship W2553936756A5024306596 @default.
• W2553936756 hasAuthorship W2553936756A5026441738 @default.
• W2553936756 hasAuthorship W2553936756A5029722841 @default.
• W2553936756 hasAuthorship W2553936756A5046242522 @default.
• W2553936756 hasAuthorship W2553936756A5071273767 @default.
• W2553936756 hasAuthorship W2553936756A5083644983 @default.
• W2553936756 hasAuthorship W2553936756A5086831338 @default.
• W2553936756 hasAuthorship W2553936756A5087011523 @default.
• W2553936756 hasConcept C126322002 @default.
• W2553936756 hasConcept C141071460 @default.
• W2553936756 hasConcept C2776694085 @default.
• W2553936756 hasConcept C2776755627 @default.
• W2553936756 hasConcept C2778336483 @default.
• W2553936756 hasConcept C2778461978 @default.
• W2553936756 hasConcept C2778720950 @default.
• W2553936756 hasConcept C2779399171 @default.
• W2553936756 hasConcept C2779429289 @default.
• W2553936756 hasConcept C2781107101 @default.
• W2553936756 hasConcept C2781413609 @default.
• W2553936756 hasConcept C2909962599 @default.
• W2553936756 hasConcept C71924100 @default.
• W2553936756 hasConcept C90924648 @default.
• W2553936756 hasConceptScore W2553936756C126322002 @default.
• W2553936756 hasConceptScore W2553936756C141071460 @default.
• W2553936756 hasConceptScore W2553936756C2776694085 @default.
• W2553936756 hasConceptScore W2553936756C2776755627 @default.
• W2553936756 hasConceptScore W2553936756C2778336483 @default.
• W2553936756 hasConceptScore W2553936756C2778461978 @default.
• W2553936756 hasConceptScore W2553936756C2778720950 @default.
• W2553936756 hasConceptScore W2553936756C2779399171 @default.
• W2553936756 hasConceptScore W2553936756C2779429289 @default.
• W2553936756 hasConceptScore W2553936756C2781107101 @default.
• W2553936756 hasConceptScore W2553936756C2781413609 @default.
• W2553936756 hasConceptScore W2553936756C2909962599 @default.
• W2553936756 hasConceptScore W2553936756C71924100 @default.
• W2553936756 hasConceptScore W2553936756C90924648 @default.
• W2553936756 hasLocation W25539367561 @default.
• W2553936756 hasOpenAccess W2553936756 @default.
• W2553936756 hasPrimaryLocation W25539367561 @default.
• W2553936756 hasRelatedWork W2016341751 @default.
• W2553936756 hasRelatedWork W2042515268 @default.
• W2553936756 hasRelatedWork W2044836346 @default.
• W2553936756 hasRelatedWork W2056874874 @default.
• W2553936756 hasRelatedWork W2059123617 @default.
• W2553936756 hasRelatedWork W2065260258 @default.
• W2553936756 hasRelatedWork W2068981294 @default.
• W2553936756 hasRelatedWork W2103654950 @default.
• W2553936756 hasRelatedWork W2121694206 @default.
• W2553936756 hasRelatedWork W2403331838 @default.
• W2553936756 isParatext "false" @default.
• W2553936756 isRetracted "false" @default.
• W2553936756 magId "2553936756" @default.
• W2553936756 workType "article" @default.